Skip to main content
Premium Trial:

Request an Annual Quote

Group Health Cooperative to Cover Exact Sciences' Cologuard

NEW YORK (GenomeWeb) – Exact Sciences today announced Group Health Cooperative will be the first health plan in Wisconsin to offer to its patients the company's recently US Food and Drug Administration-approved Cologuard colorectal cancer screening test.

The test will be available to patients covered by Group Health as part of their laboratory benefits and can be prescribed by their primary care physicians. The test was approved by the FDA last month. Simultaneously, the Centers for Medicare and Medicaid Services also issued a proposed national coverage determination for Cologuard.

Cologuard is a stool-based test that analyzes hemoglobin, multiple DNA methylation biomarkers, mutations in the KRAS gene, and the total amount of DNA.

"With colorectal cancer in particular, a high level of non-compliance with existing screening options has hampered our ability to identify the disease in its early stages when it is most treatable.," Group Health CEO Kevin Hayden said in a statement. "Making Cologuard available will hopefully encourage patients to get regular screenings and, in turn, improve survival rates for this preventable cancer.”

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.